Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$5.06 - $8.77 $100,678 - $174,496
-19,897 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$7.33 - $9.32 $74,054 - $94,159
-10,103 Reduced 33.68%
19,897 $170,000
Q2 2021

Aug 13, 2021

BUY
$9.4 - $16.85 $282,000 - $505,500
30,000 New
30,000 $317,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Weiss Asset Management LP Portfolio

Follow Weiss Asset Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Asset Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Asset Management LP with notifications on news.